William B. Horne - 30 Apr 2026 Form 5 Insider Report for Alzamend Neuro, Inc. (ALZN)

Reporting relationship: Director
Issuer ticker: ALZN
Reported as of: 30 Apr 2026
Net transaction value: $0
SEC form: 5
Accepted by SEC: 04 Aug 2026, 21:00:20 UTC
Prior SEC filing: 23 Dec 2025
Next SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: /s/ William B. Horne

Key filing fact

William B. Horne filed Form 5 for Alzamend Neuro, Inc. (ALZN) on 04 Aug 2026.

Key facts

This page summarizes William B. Horne's Form 5 filing for Alzamend Neuro, Inc. (ALZN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 21:00.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reporting Owners (1)

CIK 0001333268 Primary reporting owner

Horne William B.

Relationship: Director
Address: 3480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA
Signature: /s/ William B. Horne
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALZN transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +60,000
Change %
Price: $0.000000^*
Shares after: 60,000
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $2.33
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Horne to purchase 60,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.